BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tersolisib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tersolisib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07924930-9063@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tersolisib: Phase 1 readout est. (NCT07924930)
DESCRIPTION:Tersolisib\, phase 1.\nStudy: A Study of Tersolisib (LY4064809)
  in Participants With Kidney Impairment Compared With Participants With No
 rmal Kidney Function\nEstimated primary completion: August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tersolisib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07924930
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935317-9063@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tersolisib: Phase 2 readout est. (NCT07935317)
DESCRIPTION:Tersolisib\, phase 2\, Breast Cancer.\nStudy: A Study of Tersol
 isib (LY4064809) and Abemaciclib With Hormone Therapies in Participants Wi
 th PIK3CA-Mutated Early Breast Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tersolisib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0793
 5317
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174336-9063@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tersolisib: Phase 3 readout est. (NCT07174336)
DESCRIPTION:Tersolisib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStu
 dy: A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treat
 ments in Participants With Advanced Breast Cancer With a Genetic Change (P
 IK3CA)\nEstimated primary completion: May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tersolisib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07174336
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9063@assetmemo.bio
DTSTAMP:20261121T004535Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Tersolisib: Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Tersolisib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in C
 ombination With Other Antineoplastic Agents in Participants With Advanced 
 Solid Tumors\nEstimated primary completion: July 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/tersolisib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/tersolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
